Sequoia Financial Advisors LLC Purchases 511 Shares of Qiagen (NYSE:QGEN)

Sequoia Financial Advisors LLC boosted its position in shares of Qiagen (NYSE:QGEN) by 2.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 18,618 shares of the company’s stock after buying an additional 511 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Qiagen were worth $848,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in QGEN. US Bancorp DE lifted its stake in Qiagen by 124.4% in the first quarter. US Bancorp DE now owns 75,529 shares of the company’s stock worth $3,247,000 after acquiring an additional 41,868 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Qiagen by 25.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,689,763 shares of the company’s stock worth $72,643,000 after purchasing an additional 344,275 shares during the period. TD Asset Management Inc bought a new stake in shares of Qiagen during the 2nd quarter valued at about $2,103,000. Edgestream Partners L.P. purchased a new position in shares of Qiagen during the first quarter valued at about $1,492,000. Finally, Susquehanna International Securities Ltd. bought a new position in Qiagen in the first quarter worth about $5,731,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on QGEN. Hsbc Global Res raised Qiagen to a “hold” rating in a research report on Thursday, October 17th. Robert W. Baird increased their price objective on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Finally, HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.12.

Qiagen Stock Performance

Shares of Qiagen stock opened at $41.55 on Friday. The stock has a market cap of $9.48 billion, a price-to-earnings ratio of 27.89, a PEG ratio of 3.22 and a beta of 0.39. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.44. The firm’s 50-day moving average is $44.68 and its 200 day moving average is $43.54.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. The firm had revenue of $496.00 million for the quarter, compared to analysts’ expectations of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.53 earnings per share. Sell-side analysts anticipate that Qiagen will post 2.15 EPS for the current fiscal year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.